Certara

Radnor, PA, United States All United States companies → — Founded 2008

Biotech / Drug Discovery Healthcare Analytics / BI

Laboratory Medicine Oncology Pathology

Drug Discovery & Research Pharmacology & Dosing AI

Public Company

Website Claim this company

Products

Certara.AI

Certara

Drug Discovery & Research

Certara.AI is a specialized AI platform for life sciences that transforms how organizations harness AI by delivering specific, actionable insights. It's designed for biomedical R&D, empowering researchers with evidence-based decisions in drug discovery, clinical trials, and regulatory submissions.

Contact for pricing

See all 1 product →

About Certara

Certara is a global leader in model-informed drug development (MIDD), providing biosimulation software and technology-enabled services to pharmaceutical, biotechnology, and regulatory organizations. The company operates at the intersection of life sciences, data science, and regulatory science, aiming to transform traditional drug discovery and development to accelerate medicines to patients. Their offerings are used to simulate how drugs behave in the human body, optimize clinical trial design, and support regulatory submissions. Certara’s approach helps clients reduce the need for extensive clinical trials, accelerate regulatory approval, and increase patient access to medicines.

For physicians, Certara’s technologies and services translate into more efficient and effective drug development, ultimately leading to new and improved therapies reaching patients faster. Their biosimulation software and AI-enabled platforms, such as Certara.AI and Certara IQ, empower researchers to make data-driven decisions throughout the drug development lifecycle, from discovery and preclinical stages to clinical development, regulatory affairs, and market access. This includes optimizing trial designs, predicting drug outcomes, and generating robust evidence for regulatory submissions, which can be particularly valuable in complex therapeutic areas like oncology, rare diseases, and cell and gene therapy.

Certara also offers consulting services, providing therapeutic area-specific insights and strategic guidance to bridge knowledge gaps, optimize design parameters, and de-risk decisions in drug development. Their expertise in model-informed drug development is increasingly encouraged by regulatory agencies to improve efficiency and reduce development risk, with Certara’s tools frequently used in submissions to the U.S. Food and Drug Administration (FDA) and other global regulators.

Focus Areas

biosimulation model-informed drug development pharmacometrics physiologically based pharmacokinetic (PBPK) modeling clinical trial simulation regulatory science scientific informatics AI for drug discovery clinical data validation market access solutions medical writing

Business Intelligence

Technology

Certara.AI (AI platform for life sciences), Simcyp Simulator (PBPK modeling), Phoenix Platform (PK/PD analysis), D360 (scientific informatics), Pinnacle 21 (clinical data validation), GlobalSubmit (eCTD software), CoAuthor (GPT-powered regulatory writing platform), Certara IQ (AI-enabled QSP modeling software)

What Physicians Need to Know

Biosimulation & Model-Informed Drug Development (MIDD)

Certara is a global leader in biosimulation and MIDD, utilizing quantitative modeling, simulation, and data integration to inform critical decisions throughout the drug development lifecycle. Their solutions aim to enhance cost efficiency, speed up time to market, and deliver better treatments to patients. They offer an integrated MIDD ecosystem combining mechanistic and empirical modeling technologies and services from discovery through regulatory approval. Certara's Simcypu00ae Simulator is a key platform for Physiologically Based Pharmacokinetic (PBPK) modeling, widely used in regulatory submissions to predict drug behavior, optimize dosing, and assess drug-drug interactions. It has been used for over 120 FDA-approved novel drugs in lieu of clinical studies and is the first and only software platform to earn EMA qualification.

Pharmacometrics

Certara provides pharmacometrics services that integrate knowledge of drug exposure and response to support dose selection, safety, and efficacy. Their global team applies advanced population pharmacokinetic (PopPK), pharmacokinetic-pharmacodynamic (PK/PD), and exposure-response modeling to inform development decisions and accelerate clinical programs. They deliver regulatory-ready pharmacometrics analyses, helping optimize trial design, justify dose, and generate evidence across diverse patient populations, including special populations like pediatric and rare disease patients.

Physiologically Based Pharmacokinetic (PBPK) Modeling

Certara's Simcypu00ae Simulator is a leading PBPK modeling platform that predicts drug behavior within the human body. It plays a critical role in model-informed drug development, supporting decision-making across the drug development lifecycle. Key applications include first-in-human dose prediction, drug-drug interaction screening, pediatric and specific population modeling, absorption, food effect and formulation assessment, label claims in lieu of clinical studies, and virtual bioequivalence analysis. The Simcyp Simulator has been used for over 120 FDA-approved novel drugs in lieu of clinical studies and is licensed by 11 global regulatory agencies.

Clinical Trial Simulation

Certara's Trial Simulator software helps drug developers improve clinical trial design, aiming for a greater likelihood of trial success. It allows users to model and simulate different clinical trial scenarios, identify and assess risks, and preview expected results before significant R&D investment and patient exposure. The software offers tools to create and compare study designs, access pre-built PK/PD models, and conduct advanced analyses.

Regulatory Science

Certara offers regulatory affairs consulting services that provide tailored guidance to integrate regulatory intelligence into drug development strategies. They optimize regulatory submissions, aiming for timely approvals and successful market entry, with expertise spanning global regulatory frameworks like the FDA, EMA, and MHRA. Their multidisciplinary teams combine writers, scientists, and regulatory strategists to deliver high-quality documents aligned with health authority expectations.

Scientific Informatics

Certara's D360u2122 Scientific Informatics Platform is an industry-leading solution for small molecule and sequence-based modalities research. It empowers scientists with self-service data access, visualization, and research collaboration, integrating enterprise data from compound informatics and bioactivity parameters to operational data. D360 aims to shorten the design-make-test-analyze cycle and is used by over 6,000 research scientists worldwide.

AI for Drug Discovery

Certara is advancing an open integrated AI platform, unifying its scientific software, regulatory expertise, and proprietary datasets with AI-first, agentic frameworks. Certara.AI is a specialized GPT platform designed for biomedical R&D, trained specifically on biomedical data to provide highly specific and validated insights. This platform aims to streamline workflows, reduce costs, and accelerate timelines in drug discovery, clinical trial design, and regulatory submissions. They are partnering with NVIDIA to integrate the BioNeMo Agent Toolkit, leveraging specialized AI agents to reason over scientific models and data.

Clinical Data Validation

Certara's Pinnacle 21u00ae Enterprise (P21E) software revolutionizes clinical data validation by ensuring compliance with SDTM, ADaM, and SEND datasets, aligning with regulatory standards. P21E identifies errors and inconsistencies early, mitigating risks, accelerating submissions, and ensuring data integrity. It is the same clinical data validation software trusted by the FDA and PMDA to review submission quality.

Market Access Solutions

Certara's Market Access and Commercial solutions empower clients to craft compelling value propositions with integrated strategy, advanced analytics, and real-world evidence. They offer expertise in health economic analyses, clinical trial analytics for HTA applications, and epidemiology models. Their solutions provide strategic insights and tools to optimize pricing, reimbursement, and market entry strategies, helping to anticipate evidence gaps and overcome reimbursement hurdles.

Medical Writing

Certara offers regulatory and medical writing services that translate complex scientific data into clear, compliant, and compelling submissions. Their GenAI software, CoAuthoru2122, streamlines the drafting of regulatory documents by leveraging a leading-edge GPT, a comprehensive eCTD template library, and structured content authoring. CoAuthor aims to reduce submission timelines and enhance document quality. As of April 2026, Certara announced its definitive agreement to sell its Regulatory Writing and Medical Writing business to Veristat.

Physician Tip

For physicians, Certara's expertise translates to a faster and more efficient drug development process, potentially leading to earlier access to new and more effective therapies. Their biosimulation and PBPK modeling capabilities, particularly with the Simcypu00ae Simulator, mean that drug dosing and potential drug interactions are more thoroughly understood and predicted, even for special populations like pediatrics or those with organ impairment, reducing risks and optimizing treatment strategies. The use of AI in drug discovery and clinical trial simulation can lead to more targeted and successful trials, ultimately bringing safer and more efficacious drugs to patients. Furthermore, their focus on regulatory science and clinical data validation ensures that the data supporting new drug approvals is robust and reliable, contributing to greater confidence in prescribing decisions. Certara's market access solutions also aim to ensure that valuable therapies are accessible to patients.

Certara's technology stack includes proprietary software like the Simcypu00ae Simulator, D360u2122 Scientific Informatics Platform, Pinnacle 21u00ae Enterprise, Trial Simulator, Certara IQ (AI-enabled QSP modeling software), and CoAuthoru2122 GenAI software for medical writing. They integrate their modeling platforms with research data systems and analytical tools. Certara is also partnering with NVIDIA to advance its integrated AI platform, incorporating the BioNeMo Agent Toolkit. Their CoAuthoru2122 software seamlessly integrates with Veeva RIM to simplify digital data flows and accelerate regulatory submissions. They also partner with companies like TetraScience to enhance drug discovery and development through data-driven insights by leveraging Tetra Data within D360.

At a glance

Founded 2008

HQ Radnor, PA, United States · United States

CEO Jon Resnick

Funding Public Company

Products 1

Visit site

Products by Certara

1 product in the directory

Certara.AI

Certara

Drug Discovery & Research

Contact for pricing

What the Web Says

Certara is generally well-regarded for its scientific software and consulting services, particularly in pharmacometrics and drug development. Users appreciate the depth of its scientific tools like Phoenix and Simcyp, which are considered industry standards. As an employer, opinions are more mixed, with some highlighting a positive culture and opportunities for growth, while others point to challenges with management, workload, and compensation.

Overall: Mixed

Strengths

Industry-leading scientific software (Phoenix, Simcyp) for drug development and pharmacometrics.
Strong scientific expertise and consulting services.
Valuable tools for data analysis, modeling, and simulation in pharmaceutical research.
Opportunities for professional growth and learning in a specialized field.
Collaborative and intelligent colleagues.
Impactful work contributing to drug development.

Limitations

Software can have a steep learning curve and be complex to master.
Some users report software can be buggy or have performance issues.
Management issues, including lack of clear direction or support, are sometimes mentioned.
Work-life balance can be challenging due to high workload and demanding projects.
Compensation may not always be competitive with industry standards for some roles.
Limited opportunities for advancement in certain departments.

Based on reviews from: G2, Glassdoor, Capterra, Reddit, Healthcare IT Reviewers (general sentiment)

Last updated: 2026-10-08

Videos

News, demos, and interviews about Certara.

Loading videos...

Videos load interactively. If none appear, search YouTube for Certara →

View all on YouTube

Press & Coverage

Certara Investor Relations

Certara Reports Second Quarter 2026 Financial Results

Certara announced its second-quarter 2026 financial results, including the appointment of Julien Perrier as Chief Commercial Officer and the authorization of an additional $50 million under its share repurchase program.

2026-08

Certara

Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit

Certara is partnering with NVIDIA to enhance its open integrated AI platform with the BioNeMo Agent Toolkit, aiming to accelerate drug discovery and development by unifying scientific software, regulatory expertise, and proprietary datasets with AI-first frameworks.

2026-07

Certara Investor Relations

Certara Announces CFO Transition

Certara announced a transition in its Chief Financial Officer role.

2026-06

Certara

Certara Launches Bio Venture Catalyst for Emerging Biotechs to De-risk Investment and Accelerate Development

Certara launched Bio Venture Catalyst, an integrated strategic offering to help emerging biotech companies transform scientific innovation into investor-ready development opportunities by combining scientific, regulatory, commercial, and investor-focused expertise.

2026-06

Certara Investor Relations

Certara Reports First Quarter 2026 Financial Results

Certara released its financial results for the first quarter of 2026.

2026-05

Certara

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

Certara announced a definitive agreement to sell its Regulatory Writing and Medical Writing business to Veristat for up to $135 million, a move aimed at accelerating investment in Certara's integrated MIDD platform.

2026-04

Certara Investor Relations

Certara Simcypu00ae Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib

Certara's Simcypu00ae Simulator results were used to replace ten human trials for the Chronic Myeloid Leukemia (CML) therapy asciminib, demonstrating the growing acceptance of biosimulation in regulatory submissions.

2026-03

SaasRise

Certara Q2 Software Revenue Rises 4% | SaaS News

Certara's Q2 2026 revenue increased by 1% year-over-year to $93.3 million, with software revenue climbing 4% to $48.8 million, reflecting a strategic shift towards high-margin software after divesting its regulatory and medical-writing business.

2026-08

Frequently Asked Questions

How does Certara's biosimulation and pharmacometrics expertise benefit drug development and clinical trials?

Certara leverages biosimulation and pharmacometrics to optimize drug development by predicting drug behavior, informing dose selection, and designing more efficient clinical trials. This approach can reduce the need for certain clinical studies, accelerate timelines, and improve decision-making from early discovery through regulatory approval.

What specific software and AI tools does Certara offer for drug discovery and development, and how do they enhance the process?

Certara offers a comprehensive suite of software including Phoenix WinNonlin for PK/PD analysis, Simcyp Simulator for PBPK modeling, and Trial Simulator for clinical trial design. They also provide AI-powered tools like Certara IQu2122 for QSP, Libra for DILI prediction, and Certara.AI for life sciences, which aim to break data silos, enhance analytics, and accelerate discovery workflows.

How does Certara address regulatory science and compliance in drug submissions?

Certara provides extensive regulatory science solutions, including expert support for submissions, regulatory writing services, and clinical data validation using Pinnacle 21 Enterprise, which is also used by the FDA and PMDA. Their tools and services help ensure compliance with global data protection standards and streamline the submission process.

What are Certara's market access solutions, and how do they help bring new drugs to patients?

Certara offers market access and commercial solutions that include developing evidence-based pricing, reimbursement, and patient access strategies. They leverage real-time, real-world data and AI technologies to strengthen market positioning, secure optimal coverage, and demonstrate a therapy's value to payers and stakeholders.

What kind of medical writing support does Certara provide, especially concerning regulatory documents?

Certara offers comprehensive medical and regulatory writing services, including the drafting of regulatory documents, clinical study reports, and patient narratives. They utilize AI-powered software like CoAuthoru2122 to streamline content creation, ensure consistency, and accelerate submission timelines.

What is Certara's approach to data security and compliance with privacy regulations?

Certara is committed to data privacy and security, holding ISO 27001 certification for its Information Security Management System. They implement robust security controls, conduct risk assessments, and ensure compliance with global data protection standards like GDPR and HIPAA, often processing de-identified or pseudonymized clinical data.

What is Certara's company stability and outlook, including partnerships and financial performance?

Certara is a global leader in model-informed drug development, serving over 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies. They have strategic partnerships with organizations like NVIDIA and A2 Healthcare to integrate AI and expand their reach. While facing some recent challenges, analysts generally have a positive outlook, predicting profitability and potential for future growth.